A Study to Evaluate the Efficacy and Safety of SHR8008 vs. Fluconazole in Subjects With Acute Vulvovaginal Candidiasis

Inclusion Criteria: 1. Females ≥18 and ≤75 years old; 2. Clinical diagnosis with VVC episodes at screening, signs and symptoms score of ≥ 7, with a documented positive potassium hydroxide (KOH) or Gram staining; 3. Subjects of childbearing potential must have a negative pregnancy test result at screening and agree to use highly effective contraceptive measures throughout the study; 4. Willing to sign the informed consent form to participate in this study. Exclusion Criteria: 1. Have recurrent vulvovaginal candidiasis (RVVC) as defined by 4 or more confirmed VVC episodes in the past 12 months or history of RVVC; 2. Presence of concomitant vulvovaginitis caused by other pathogens; 3. History of cervical cancer, or "cervical intraepithelial neoplasia or malignancy" or "atypical squamous cells of undetermined significance (ASCUS)" as indicated by Pap test or other tests reported within 1 year before screening; 4. Moderate to severe hepatic and/or renal disorders; 5. Have received systemic or vulvovaginal antifungal drugs, antibacterials, antitrichomonal, CYP3A4 substrates or inducers or inhibitors, or vulvovaginal corticosteroids within 7 days prior to randomization; 6. Have received any estrogen replacement therapy or vaginal topical products within 7 days prior to randomization; 7. Have received systemic corticosteroid therapy within 30 days or systemic immunosuppressant therapy within 90 days prior to randomization; 8. Presence of significant laboratory abnormalities at screening; 9. QTc interval greater than 470 ms or other clinically significant ECG abnormalities at screening; 10. Have planned surgeries or other medical procedures that may impact compliance with the protocol; 11. Known history of hypersensitivity or intolerance to azole antifungal drugs; 12. Being in the menstrual period, pregnant, or lactating at screening, or planning to become pregnant during the study period; 13. History of narcotic or drug abuse or alcoholism within 6 months prior to screening; 14. Have participated in another clinical study and received the investigational drug containing active ingredient within 30 days prior to screening; 15. Other conditions unsuitable for participation in the study per investigator's judgment.